Dose ranges reflect commonly studied amounts in published research models. This is not medical advice. For research use only. Not for human consumption.
Protocol Comparison
Recovery
Research dose range
Standard research range
150 - 250 mcg
The most widely documented protocol dose for each peptide.
Research focus
Growth hormone release
Observed window
Sleep quality shifts within 1-2 weeks; body composition/IGF-1 response over 8-12 weeks
Administration
once or twice daily, 30-60 min before meals or at bedtime on an empty stomach; 8-12 week cycle, 4-week break
Primary pathway
GHRH receptor (CJC-1295), Ghrelin receptor / GHS-R (Ipamorelin)
Dosing reflects the 1:1 ratio standard across CJC-1295 (no DAC)/Ipamorelin research protocols — each peptide dosed identically per injection. Individual compounds have separate human research; the combined blend itself has no dedicated published clinical trial. For research use only.
PROTOCOL BENEFITS
◆
CJC-1295 extends and strengthens each natural GH pulse by binding GHRH receptors — priming the pituitary for a larger release.
◆
Ipamorelin triggers that release through a completely separate pathway — the ghrelin receptor — without the cortisol or prolactin elevation older secretagogues carry.
◆
Together, the two produce a documented synergistic effect — 2-3x greater GH output than either compound alone.
SCIENCE
CJC-1295 and Ipamorelin reach the same goal — growth hormone release — through two separate receptors. CJC-1295 extends and strengthens each natural GH pulse; Ipamorelin triggers it directly, without the cortisol or prolactin spike older secretagogues cause.
The no-DAC choice matters: its 30-minute half-life matches Ipamorelin's pulsatile rhythm, unlike the DAC version's 6-8 day flat elevation. Each compound has separate human research behind it — the combined blend itself doesn't have a dedicated trial, though it's the most widely used GH-peptide stack in the research community.
WHAT TO EXPECT
Improved sleep quality is often the earliest reported change, typically within 1-2 weeks. Body composition and recovery effects build progressively over an 8-12 week cycle as IGF-1 levels respond.
PROTOCOL NOTE
5mg CJC-1295 (no DAC) + 5mg Ipamorelin per vial. For research use only. Full documentation included with every order.
FAQ
The no-DAC version's short half-life matches Ipamorelin's pulsatile pattern. The DAC version lasts 6-8 days, producing sustained elevation instead of the natural pulse-and-release rhythm this pairing is built around.
Yes — unlike some blends, this is the standard convention. Both compounds are dosed in the same range, and pre-mixed 1:1 vials are the most common format across the research community.
